The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**CALGB-100104**: A randomized phase III trial testing the role of lenalidomide following autologous transplantation for multiple myeloma, was closed early after interim analysis showed that lenalidomide resulted in a 58% reduced risk of progression compared to placebo. This is the first randomized trial to show benefit of maintenance therapy following transplantation for myeloma.

**E1199**: Evaluated the effect of black race on outcomes by hormone receptor (HR) and HER2 expression in patients treated with standard adjuvant therapy. Observation was made of significant inferior disease-free survival (DFS) and overall survival in black subjects who received chemohormonal therapy with HR+ disease (adjusted for other prognostic factors and BMI) but not in other phenotypes (“triple negative” [TN] or HER-s pos). This observation suggests that factors other than disparities in care or more advanced or aggressive disease may have contributed to recurrence.

**N9831**: DFS is significantly improved with the addition of 52 weeks of trastuzumab (H) (sequentially or concurrently) to doxorubicin and cyclophosphamide then paclitaxel (AC→T). There is a statistically significant 33% reduction in the risk of an event with the sequential addition of H following AC→T. There is a strong trend for a 25% reduction in the risk of an event with starting H concurrently with T (AC→T+H→H) relative to sequentially after T (AC→T→H). Therefore, based on a positive risk/benefit ratio, it is recommended that trastuzumab be incorporated in a concurrent fashion with T chemotherapy.
Cooperative Group Abstracts

Breast Cancer

ACRIN

http://rsna2009.rsna.org/search/event_display.cfm?am_id=2&em_id=8002965&printmode=Y&autoprint=N
Protocol(s): ACRIN-6666

http://rsna2009.rsna.org/search/event_display.cfm?am_id=2&em_id=8002537&printmode=Y&autoprint=N
Protocol(s): ACRIN-6666

Protocol(s): ACRIN-6666

Protocol(s): ACRIN-6652

http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf
Protocol(s): ACRIN-6657

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8009188&printmode=Y&autoprint=N
Protocol(s): ACRIN-6657
CALGB


Protocol(s): INT-0148
Other Participating Group(s): ECOG, NCCTG, SWOG


Protocol(s): CALGB-9342, CALGB-9840


Protocol(s): CALGB-49907


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40158
Protocol(s): INT-0148
Other Participating Group(s): ECOG, NCCTG, SWOG


Protocol(s): CALGB-150007


Protocol(s): CALGB-150007
ECOG

Protocol(s): E2197
Other Participating Group(s): CALGB, NCCTG, SWOG

Protocol(s): E1199
Other Participating Group(s): CALGB, NCCTG, SWOG

Protocol(s): E1104

NCCTG

http://www.redjournal.org/article/S0360-3016(09)01178-X/fulltext
Protocol(s): N9831
Other Participating Group(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG

Protocol(s): N02C1
Protocol(s): N06C4

Protocol(s): N9831

Protocol(s): N9831
Other Participating Group(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG

Protocol(s): N0234, N0436, N0338, N0437, N0336


NCIC Clinical Trials Group

Protocol(s): JMA17
Other Participating Group(s): CALGB, ECOG, NCCTG, SWOG

Other Participating Group(s): CALGB, ECOG, NCCTG, SWOG


NSABP


Protocol(s): NSABP-B-24

SWOG

Protocol(s): INT-0100
Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trails Group

Protocol(s): S0221

CNS Cancer

COG

Protocol(s): A9961

Protocol(s): ANBL0032
NCCTG

Protocol(s): Multiple Trials

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/C56?sid=7d1823a4-4f94-4e7b-8fbb-790ceeb7a4660
Protocol(s): N057K

Gastrointestinal Cancer

ACRIN

http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf
Protocol(s): ACRIN-6673

http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf
Protocol(s): ACRIN-6664

Protocol(s): ACRIN-6664

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8006966&printmode=Y&autoprint=N
Protocol(s): ACRIN-6664
NSABP

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/A201?sid=7c3c5ddd-3ad1-42ed-aaae-524b51f68f1d
Protocol(s): NSABP-C-07

RTOG

http://www.redjournal.org/article/S0360-3016(09)01126-2/fulltext#sec2
Protocol(s): RTOG-87-04, RTOG-98-11
Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, SWOG

http://www.redjournal.org/article/S0360-3016(09)01080-3/fulltext
Protocol(s): RTOG-0529

http://www.redjournal.org/article/S0360-3016(09)01189-4/fulltext
Protocol(s): RTOG-97-04
Other Participating Group(s): ECOG, SWOG

SWOG

http://www.redjournal.org/article/S0360-3016(09)01434-5/fulltext
Protocol(s): S0414
Genitourinary Cancer

**RTOG**

Protocol(s): RTOG-92-02, RTOG-94-03

Protocol(s): RTOG-98-05

Protocol(s): RTOG-94-08

Protocol(s): PROG-95-09

[http://www.caro-acro.ca/meetings___Education/Annual_Scientific_Meetings/23rd_Annual_Scientific_Meeting_September_30_-_October_3__2009__Quebec_City.htm](http://www.caro-acro.ca/meetings___Education/Annual_Scientific_Meetings/23rd_Annual_Scientific_Meeting_September_30_-_October_3__2009__Quebec_City.htm)  
Protocol(s): RTOG-92-02, RTOG-94-13

**SWOG**

Protocol(s): Multiple Trials
Lerner, SP: P53 and Other Biomarkers. World Urologic Oncology Federation Meeting, Shanghai, China, Nov, 2009.
Protocol(s): SWOG-4B951

http://www.redjournal.org/article/S0360-3016(09)01090-6/fulltext
Protocol(s): INT-0086
Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG

Gynecologic Cancer

RTOG

http://www.redjournal.org/article/S0360-3016(09)01397-2/fulltext
Protocol(s): RTOG-C-0128

http://www.redjournal.org/article/S0360-3016(09)01250-4/fulltext
Protocol(s): Multiple Trials

http://www.redjournal.org/article/S0360-3016(09)02504-8/fulltext
Protocol(s): RTOG-0418

http://www.redjournal.org/article/S0360-3016(09)01256-5/fulltext
Protocol(s): RTOG-0116, RTOG-C-0128
Head and Neck Cancer

**ECOG**

http://www.redjournal.org/article/S0360-3016(09)01100-6/fulltext  
Protocol(s): E3303

**RTOG**

Protocol(s): RTOG-0129

http://www.redjournal.org/article/S0360-3016(09)01099-2/fulltext  
Protocol(s): RTOG-0234

Leukemia, Myelodysplasia, and Transplantation

**CALGB**

Protocol(s): CALGB-9665, CALGB-20202, CALGB-8461

Protocol(s): CALGB-100101  
Other Participating Group(s): ECOG
Protocol(s): CALGB-10101

Protocol(s): CALGB-8461

Rai KR, Peterson BL, Appelbaum FR, Tallman MS, Belch A, Morrison VA, Larson RA: Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2009; 114(22): Abst. 536.  
Protocol(s): CALGB-9011  
Other Participating Group(s): ECOG, NCIC Clinical Trials Group, SWOG

Protocol(s): CALGB-10102

Protocol(s): CALGB-9720, CALGB-10201, CALGB-8923, CALGB-8525, CALGB-9420

Protocol(s): CALGB-9712
**COG**

Protocol(s): AALL05B1

Protocol(s): CCG-2941, CCG-2961, CCG-2891

Protocol(s): CCG-2961, AAML03P1

Protocol(s): AALL06B1

Protocol(s): AALL0031

Protocol(s): AALL03B1
Protocol(s): AALL0031

Protocol(s): POG-9605

Protocol(s): AAML0523

Protocol(s): CCG-1961

Protocol(s): POG-9404

Haugen MS, Toomey DA, Byron P: Acute Lymphoblastic Leukemia in the Adolescent and Young Adult: An Education Module for Clinical Trial, CALGB 10403. Association of Pediatric Hematology/Oncology Nurses (APHON), Orlando, FL, Sep, 2009. 
[http://www.aphon.org/meetings/conference/]
Protocol(s): AALL0232

Protocol(s): AALL03B1, AALL0232, AALL0331
Protocol(s): AALL05B1

http://www3.interscience.wiley.com/journal/122588312/abstract
Protocol(s): POG-9906

Protocol(s): CCG-2941, CCG-2961

Protocol(s): CCG-1991

Protocol(s): AALL05B1

Protocol(s): POG-9906

Protocol(s): CCG-2941, CCG-2961
Protocol(s): POG-9421

Protocol(s): POG-9900

[http://www.musictherapy.org/conference/confindex.html](http://www.musictherapy.org/conference/confindex.html)  
Protocol(s): ANUR0631

[http://www.musictherapy.org/conference/confindex.html](http://www.musictherapy.org/conference/confindex.html)  
Protocol(s): ANUR0631

Protocol(s): P9407

Protocol(s): ANUR0631

Protocol(s): ANUR0631

Protocol(s): AAML03P1
Protocol(s): AALL03B1, AALL0434

Protocol(s): POG-9906

ECOG

Protocol(s): E1900

SWOG

Protocol(s): S0530

Protocol(s): S0106
Lymphoma and Plasma Cell Disorders

**CALGB**


Protocol(s): CALGB-100104

**COG**


http://www3.interscience.wiley.com/journal/122588312/abstract

Protocol(s): ANHL01P1


Protocol(s): ANHL01P1

**ECOG**


Protocol(s): E2404


Protocol(s): E1405
NCCTG

Protocol(s): N0489

Protocol(s): N0489

NCIC Clinical Trials Group

Protocol(s): NCIC-182

SWOG

Protocol(s): SWOG-8819

Protocol(s): SWOG-8819

Protocol(s): SWOG-8819
Protocol(s): S9911, S9800, SWOG-8809

Protocol(s): SWOG-8819

Lung Cancer

ACRIN

http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf  
Protocol(s): ACRIN-6654

ECOG

http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): E1594

NCCTG

http://ncitranslates.nci.nih.gov/docs/TSM2%20Abstract%20Book%20FINAL.pdf  
Protocol(s): N0026

http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): N0621
http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): N0623

http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): N0028

RTOG

http://www.redjournal.org/article/S0360-3016(09)01074-8/fulltext  
Protocol(s): RTOG-0515

http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): RTOG-0117

http://journals.lww.com/jto/toc/2009/09001  
Protocol(s): RTOG-0213

http://www.redjournal.org/article/S0360-3016(09)01420-5/fulltext  
Protocol(s): RTOG-0324
Protocol(s): RTOG-0236

Protocol(s): RTOG-0239

Protocol(s): RTOG-0239

Protocol(s): RTOG-0214


Protocol(s): RTOG 0123
Protocol(s): RTOG-0214

Protocol(s): RTOG-0236

Protocol(s): RTOG-0236


Protocol(s): RTOG-0212

**SWOG**

Protocol(s): S0424

Protocol(s): S9806, S0003, SWOG-9308
http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S0536

http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S0220
Other Participating Group(s): ACOSOG, CALGB, ECOG, NCCTG, NCIC Clinical Trials Group

http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S0124

http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S0424

http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S9900
Other Participating Group(s): ACOSOG, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG

http://journals.lww.com/jto/toc/2009/09001
Protocol(s): S0424

Sarcoma/Bone and Soft Tissue Cancers

COG

http://www3.interscience.wiley.com/journal/122588312/abstract
Protocol(s): AOST0331
http://www3.interscience.wiley.com/journal/122588312/abstract
Protocol(s): AOST0331

http://www.ctos.org/meeting/2009/program.asp
Protocol(s): ARST0431, ARST0121

Other Cancer

COG

http://www.ctos.org/meeting/2009/program.asp
Protocol(s): ADVL0414

NCCTG

Protocol(s): Multiple Trials

Protocol(s): Multiple Trials

RTOG

http://www.redjournal.org/article/S0360-3016(09)01263-2/fulltext
Protocol(s): Multiple Trials, RTOG 0123
Protocol(s): SWOG-9217
Other Participating Group(s): CALGB, ECOG, NCCTG
NCI/Clinical Trials Cooperative Groups National Meetings Report

NCI/Clinical Trials Cooperative Groups National Meetings Report

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.